Skip to main content
. 2022 Apr 1;28(11):2237–2247. doi: 10.1158/1078-0432.CCR-21-2326

Figure 4.

Figure 4. rPFS by AR-v7 status. A, The PFS of samotolisib + enzalutamide arm versus placebo + enzalutamide arm in patients without AR v-7. B, The PFS of samotolisib + enzalutamide arm versus placebo + enzalutamide arm in patients with AR v-7.

rPFS by AR-v7 status. A, The PFS of samotolisib + enzalutamide arm versus placebo + enzalutamide arm in patients without AR-v7. B, The PFS of samotolisib + enzalutamide arm versus placebo + enzalutamide arm in patients with AR-v7.